Unilife aims prefilled syringes at patients who self-inject

Last week, we mentioned Unilife, a York, PA-based developer of drug-delivery systems, is aiming its safety syringes at the market for healthcare workers increasingly concerned about needle-stick injuries. This week, Unilife announced its new line of auto-injectors are meant for the rising numbers of patients who inject themselves outside a healthcare setting.

Driving this market is the "development and commercial launch of biologics, biosimilar and other drugs suitable for patient self-injection as well as the enforcement of laws in the U.S., Europe and other emerging markets seeking to prevent needlestick injuries," according to a company statement.

Unilife says that its auto-injectors "enable patients to inject a fixed dose of medication with the simple push of a button, without ever seeing the needle."

"Conventional auto-injector technologies can cause some confusion among patients, as it can be difficult to determine just when the full dose has been delivered," Unilife CEO Alan Shortall said in a statement. "For Unifill Auto-Injectors, once a patient hears the audible-tactile indication signaling the activation of the safety mechanism, they know the dose has been fully administered and the device can be safely taken away from the body."

- read the release from Unilife

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.